$467 Million is the total value of Third Rock Ventures, LLC's 4 reported holdings in Q2 2014. The portfolio turnover from Q1 2014 to Q2 2014 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AGIO | Sell | Agios Pharmaceuticals, Inc. | $178,473,000 | -18.1% | 3,895,090 | -30.0% | 38.11% | -1.3% |
| FMI | Sell | Foundation Medicine, Inc. | $132,838,000 | -37.5% | 4,927,234 | -25.0% | 28.36% | -24.8% |
| BLUE | bluebird bio, Inc. | $93,223,000 | +69.6% | 2,416,974 | 0.0% | 19.90% | +104.3% | |
| EBIO | Eleven Biotherapeutics, Inc. | $63,812,000 | -18.8% | 4,841,591 | 0.0% | 13.62% | -2.2% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2014-07-30
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| ELEVEN BIOTHERAPEUTICS INC | 7 | Q3 2015 | 13.9% |
| Foundation Medicine, Inc. | 6 | Q1 2015 | 44.6% |
| SAGE THERAPEUTICS INC | 5 | Q3 2015 | 66.7% |
| Agios Pharmaceuticals, Inc. | 5 | Q4 2014 | 38.6% |
| bluebird bio, Inc. | 5 | Q4 2014 | 22.4% |
| ZAFGEN INC | 5 | Q3 2015 | 17.8% |
| BLUEPRINT MEDICINES CORP | 2 | Q3 2015 | 20.4% |
| GLOBAL BLOOD THERAPEUTICS IN | 1 | Q3 2015 | 58.1% |
View Third Rock Ventures, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2015-11-03 |
| 13F-HR | 2015-07-30 |
| 13F-HR | 2015-04-29 |
| 13F-HR | 2015-01-26 |
| 13F-HR | 2014-10-22 |
| 13F-HR | 2014-07-30 |
| 13F-HR | 2014-04-30 |
| 13F-HR | 2014-02-14 |
View Third Rock Ventures, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.